Hepatobiliary complications of immune checkpoint inhibitors in cancer DOI Creative Commons
Donna Zhuang, David Zhang, Stephen M. Riordan

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(4), P. 955 - 970

Published: July 26, 2024

Immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of cancer therapy. Over last decade, both their primary focus in trials and clinical application exponentially risen, with repeated demonstrations efficacy improving survival various types. The adverse effects these drugs on organ systems were recognised early phase studies. Given relatively new emergence market, there has been increasing interest into short- long-term management ICIs real-world settings. ICI-related hepatobiliary toxicities are often challenging to diagnose difficult distinguish from other causes deranged liver biochemical tests. aim this review is provide an up-to-date detailed exploration complications ICIs, including pathogenesis approaches diagnosis management.

Language: Английский

Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges DOI Creative Commons
Lily Dara,

Eleonora De Martin

Liver International, Journal Year: 2025, Volume and Issue: 45(2)

Published: Jan. 27, 2025

ABSTRACT Over the past decade, immune checkpoint inhibitors (ICIs) have transformed treatment of cancer, though they come with risk immune‐related adverse (irAEs) events such as hepatotoxicity or Immune‐mediated Liver Injury from Checkpoint Inhibitors (ILICI). ILICI is a serious irAE that, when severe, requires cessation ICI and initiation immunosuppression. Cytotoxic T Lymphocytes (CTLs) play central role in ILICI; however, are just part picture immunotherapy broadly impacts all aspects microenvironment can directly indirectly activate innate adaptive cells. Clinically, our understanding this entity grows, we encounter new challenges. The presentation heterogeneous respect to latency, pattern injury (hepatitis vs. cholangitis) severity. This review focuses on knowledge regarding factors, including refractory steroids. An emerging topic, possibility rechallenge while accepting some risk, patients who experience but require immunotherapy, also discussed. provides an update current knowns unknowns highlights several gaps where studies needed.

Language: Английский

Citations

2
Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: a retrospective analysis based on clinical study and real-world data DOI
Bitao Wang, Shaowei Zhuang, Shengnan Lin

et al.

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Language: Английский

Citations

1
Drug induced cholestatic liver diseases DOI
Einar S. Björnsson, Harshad Devarbhavi

Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 8, 2024

Cholestatic DILI is an important and frequently challenging differential diagnosis in patients presenting with elevated liver tests predominant elevation alkaline phosphatase. A number of competing etiologies need to be ruled out, such as hepatobiliary malignancy, choledocholithiasis, cholestatic forms viral hepatitis, cholestasis sepsis, primary secondary cholangitis, right-sided cardiac failure name a few. Important advances have occurred the understanding knowledge clinical phenotypes, new etiological agents, risk factors, pathophysiology, genetic determinants drug-induced since last review on was published Hepatology 2011. Secondary sclerosing cholangitis (SSC) due drugs has been well documented for several different drugs. Checkpoint inhibitors are one types shown lead cholangitis. Several herbal dietary supplements recently injury. factors identified decade, pathogenesis behind injury better defined. In this review, focus diagnostic approach description phenotypes vanishing bile duct syndrome. Furthermore, provides overview determinants, pathophysiology transporters leading cholestasis. Management, areas uncertainty, future direction also presented.

Language: Английский

Citations

4
Risk factors and prediction for DILI in clinical practice DOI
Helgi K. Björnsson, Einar S. Björnsson

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Introduction Drug-induced liver injury is an important adverse effect and can be caused by various medications, including novel therapeutic agents. The risk stratification of patients susceptible DILI a growing field.

Language: Английский

Citations

0
Causal Association Between Circulating Inflammatory Proteins and Autoimmune Liver Disease: a Bidirectional Two-Sample Mendelian Randomization Study DOI Creative Commons
Lina Leng, Minghao Yin, Tao Xu

et al.

ImmunoTargets and Therapy, Journal Year: 2025, Volume and Issue: Volume 14, P. 279 - 289

Published: March 1, 2025

To investigate whether there is a direct causal relationship between circulating inflammatory proteins and autoimmune liver disease (AILD). We collected genetic data for various AILD from the Genome Wide Association Studies (GWAS) dataset. The latest research provides GWAS 91 associated with inflammation. Perform bidirectional two sample Mendelian randomization (MR) analysis using inverse variance weighted (IVW) to determine AILD, use Egger method (MR Egger), median (WM), mode as supplementary evaluations. In addition, we conducted sensitivity analysis. Positive MR showed that CDCP1 (OR=1.363, p=0.0465) IL-18 (OR=1.416, p=0.0477) were higher including hepatitis (AIH) risk. Higher CXCL11 (OR=1.574, p=9.23×10-5) an increased risk of primary biliary cholangitis (PBC). Lower levels three PBC. TNFSF12 (OR=1.827, p=0.0001, p_adj_fdr=0.0063), CD6 isoform (OR=1.126, p=0.0389), CCL20 (OR=1.880, p=0.0395) are sclerosing (PSC). Reverse imaging PBC may promote expression CCL4 (OR=1.023, p=0.0201) OSM (OR=1.022, p=0.0236). PSC five proteins. Sensitivity further excluded effects heterogeneity horizontal pleiotropy. This study indicates potential association which become new diagnostic indicator or drug target clinical application in prevention treatment AILD. However, investigation needed.

Language: Английский

Citations

0
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management DOI
Evangelos Triantafyllou, Cathrin Gudd, Lucia Possamai

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 11, 2024

Language: Английский

Citations

2
Hepatobiliary complications of immune checkpoint inhibitors in cancer DOI Creative Commons
Donna Zhuang, David Zhang, Stephen M. Riordan

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(4), P. 955 - 970

Published: July 26, 2024

Immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of cancer therapy. Over last decade, both their primary focus in trials and clinical application exponentially risen, with repeated demonstrations efficacy improving survival various types. The adverse effects these drugs on organ systems were recognised early phase studies. Given relatively new emergence market, there has been increasing interest into short- long-term management ICIs real-world settings. ICI-related hepatobiliary toxicities are often challenging to diagnose difficult distinguish from other causes deranged liver biochemical tests. aim this review is provide an up-to-date detailed exploration complications ICIs, including pathogenesis approaches diagnosis management.

Language: Английский

Citations

1